Black Diamond Therapeutics, Inc. (BDTX)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
2.23 USD
-0.04
(-1.762%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.23 |
Hot Take ↕ | Aug. 22, 2026, 4:19 a.m. EDT
The investment case here is severely compromised by a brutal five-year price trajectory that has erased over 90% of the company's value. Despite a recent quarterly earnings beat and a 'strong buy' recommendation from analysts, the market has priced in a catastrophic failure of the business model, likely due to the lack of commercialized products and persistent losses. The balance sheet, while currently liquid, faces an existential threat given the massive cash burn and the absence of a clear path to profitability without further dilution. The recent price action shows a fragile recovery attempt, but the statistical forecast offers no directional guidance, and the options market is screaming caution with heavy put positioning. This is a high-risk speculative vehicle where the gap between analyst optimism and the reality of the balance sheet is too wide to ignore. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.160655 |
| AutoTheta | 0.189836 |
| AutoARIMA | 0.194773 |
| AutoETS | 0.195052 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.154 |
| Excess Kurtosis | 0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.66 |
| Market Cap | 128,121,856 |
| Forward P/E | -2.23 |
| Beta | 3.29 |
| Website | https://www.blackdiamondtherapeutics.com |
As of Aug. 22, 2026, 4:19 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by massive put volume at the $5.00 strike for September expiration compared to negligible call interest. While there is some call activity at higher strikes ($7.50) suggesting a speculative 'lottery ticket' mentality, the overwhelming majority of open interest and volume in puts indicates a bearish bias where traders are betting against a potential collapse or stagnation rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.20357144 |
| Address1 | 245 First Street |
| Address2 | 18th Floor |
| All Time High | 46.25 |
| All Time Low | 1.18 |
| Ask | 2.3 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 571,930 |
| Average Daily Volume3 Month | 1,215,122 |
| Average Volume | 1,215,122 |
| Average Volume10Days | 571,930 |
| Beta | 3.288 |
| Bid | 1.65 |
| Bid Size | 2 |
| Book Value | 1.673 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.23 |
| Current Ratio | 7.284 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.2899 |
| Day Low | 2.17 |
| Debt To Equity | 17.66 |
| Display Name | Black Diamond Therapeutics |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -44,349,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.78 |
| Enterprise Value | 34,585,856 |
| Eps Current Year | -0.56667 |
| Eps Forward | -1.0 |
| Eps Trailing Twelve Months | -0.74 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9077 |
| Fifty Day Average Change | 0.32230008 |
| Fifty Day Average Change Percent | 0.16894695 |
| Fifty Two Week Change Percent | -20.357143 |
| Fifty Two Week High | 4.94 |
| Fifty Two Week High Change | -2.71 |
| Fifty Two Week High Change Percent | -0.548583 |
| Fifty Two Week Low | 1.6 |
| Fifty Two Week Low Change | 0.63 |
| Fifty Two Week Low Change Percent | 0.39374998 |
| Fifty Two Week Range | 1.6 - 4.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,481,000,000 |
| Float Shares | 52,601,778 |
| Forward Eps | -1.0 |
| Forward P E | -2.23 |
| Free Cashflow | -23,577,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 21 |
| Fullday Change | -0.04 |
| Fullday Change Percent | -1.76211 |
| Fullday Price | 2.23 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0064999997 |
| Held Percent Institutions | 0.72519994 |
| Implied Shares Outstanding | 57,453,747 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Black Diamond Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 128,121,856 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_424913244 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -42,555,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 130,420,005 |
| Number Of Analyst Opinions | 7 |
| Open | 2.28 |
| Operating Cashflow | -32,837,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 617 252 0848 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.23 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 2.27 |
| Price Eps Current Year | -3.935271 |
| Price Hint | 4 |
| Price To Book | 1.3329349 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 6.975 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -1.76211 |
| Regular Market Day High | 2.2899 |
| Regular Market Day Low | 2.17 |
| Regular Market Day Range | 2.17 - 2.2899 |
| Regular Market Open | 2.28 |
| Regular Market Previous Close | 2.27 |
| Regular Market Price | 2.23 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 521,910 |
| Return On Assets | -0.19112 |
| Return On Equity | -0.37215 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 57,453,747 |
| Shares Percent Shares Out | 0.107700005 |
| Shares Short | 6,185,629 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,851,617 |
| Short Name | Black Diamond Therapeutics, Inc |
| Short Percent Of Float | 0.1547 |
| Short Ratio | 9.51 |
| Source Interval | 15 |
| State | MA |
| Symbol | BDTX |
| Target High Price | 14.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 110,506,000 |
| Total Cash Per Share | 1.923 |
| Total Debt | 16,970,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.45445 |
| Two Hundred Day Average Change | -0.22444987 |
| Two Hundred Day Average Change Percent | -0.0914461 |
| Type Disp | Equity |
| Volume | 521,910 |
| Website | https://www.blackdiamondtherapeutics.com |
| Zip | 2,142 |